Baroda BNP Paribas Value Fund
(An open ended equity scheme following a value investment strategy)
Baroda BNP Paribas Value Fund
(An open ended equity scheme following a value investment strategy)
April 2025

April 2025


Investment Objective

The investment objective of the scheme is to generate long-term capital appreciation from a diversified portfolio of predominantly equity and equity related instruments by following a value investment strategy. However, there can be no assurance that the investment objectives of the Scheme will be realized. The Scheme does not guarantee/indicate any returns.

NAV Details (As on April 30, 2025)
Regular Plan - IDCW Option : ₹12.3006
Regular Plan - Growth Option : ₹13.4910
Direct Plan - IDCW Option : ₹12.6370
Direct Plan - Growth Option : ₹13.8590
Benchmark Index (Tier 1)

Nifty 500 TRI

Date of Allotment

June 7, 2023

Fund Manager
Fund Manager Managing fund since Experience
Mr. Shiv Chanani 07-Jun-23 21 years
Mr. Himanshu Singh 21-Oct-24 10 years
Load Structure

Exit Load: • If units of the Scheme are redeemed or switched out up to 10% of the units (the limit) within 1 year from the date of allotment - Nil. • If units of the scheme are redeemed or switched out in excess of the limit within 1 year from the date of allotment - 1% of the applicable NAV. • If units of scheme are redeemed or switched out after 1 year from the date of allotment - Nil.
For detailed load structure please refer Scheme Information Document.


Lumpsum Details

Minimum Amount: Lumpsum investment:
₹ 5,000 and in multiples of ₹ 1 thereafter.
Minimum Additional Application Amount:₹ 1,000 and in multiples of ₹ 1 thereafter.


Monthly AAUM## As on April 30, 2025 : ₹ 1,295.21 Crores
AUM## As on April 30, 2025 : ₹ 1,319.17 Crores

## including inter-scheme Investments, if any, by other schemes of Baroda BNP Paribas Mutual Fund, as may be applicable

EQUITY HOLDINGS % of Net Assets
Banks 17.89%
ICICI Bank Limited 7.14%
HDFC Bank Limited 6.57%
Kotak Mahindra Bank Limited 4.18%
Pharmaceuticals & Biotechnology 12.08%
Alkem Laboratories Limited 2.33%
Divi's Laboratories Limited 2.31%
Sun Pharmaceutical Industries Limited 1.67%
Lupin Limited 1.59%
Torrent Pharmaceuticals Limited 1.26%
Cipla Limited 1.18%
Sanofi India Limited 0.99%
Sanofi Consumer Healthcare India Limited 0.75%
IT - Software 9.33%
Infosys Limited 5.40%
Tata Consultancy Services Limited 3.93%
Power 6.51%
NTPC Limited 2.96%
SJVN Limited 1.92%
Power Grid Corporation of India Limited 1.63%
Petroleum Products 6.48%
Reliance Industries Limited 5.33%
Hindustan Petroleum Corporation Limited 1.15%
Gas 5.64%
Mahanagar Gas Limited 2.76%
Petronet LNG Limited 1.01%
GAIL (India) Limited 1.00%
Gujarat State Petronet Limited 0.87%
Finance 4.63%
Power Finance Corporation Limited 1.96%
Mas Financial Services Limited 1.72%
India Shelter Finance Corporation Limited 0.95%
Electrical Equipment 3.62%
Bharat Heavy Electricals Limited 2.06%
GE Vernova T&D India Limited 1.56%
Consumer Durables 3.26%
Blue Star Limited 1.85%
Crompton Greaves Consumer Electricals Limited 1.41%
Auto Components 3.22%
Jtekt India Limited 1.27%
Exide Industries Limited 1.07%
Sundaram Clayton Limited 0.88%
Automobiles 3.21%
TVS Motor Company Limited 1.22%
Eicher Motors Limited 1.06%
Maruti Suzuki India Limited 0.93%
Insurance 3.04%
ICICI Prudential Life Insurance Company Limited 1.63%
HDFC Life Insurance Company Limited 1.41%
Consumable Fuels 2.77%
Coal India Limited 2.77%
Construction 2.53%
Larsen & Toubro Limited 2.53%
Telecom - Services 1.92%
Indus Towers Limited 1.92%
Oil 1.56%
Oil India Limited 1.56%
Cement & Cement Products 1.50%
UltraTech Cement Limited 1.50%
Aerospace & Defense 1.43%
Bharat Electronics Limited 1.43%
Agricultural Food & other Products 1.09%
AWL Agri Business Limited 1.09%
Beverages 0.99%
Varun Beverages Limited 0.99%
LESS THAN 0.75% EXPOSURE 2.16%
TOTAL EQUITY HOLDING 94.86%
FIXED INCOME HOLDINGS Rating % of Net Assets
TREASURY BILL 1.50%
364 Days Tbill (MD 10/07/2025) SOV 0.75%
364 Days Tbill (MD 23/05/2025) SOV 0.38%
364 Days Tbill (MD 04/09/2025) SOV 0.37%
Total Fixed Income Holdings 1.50%
TREPS, Cash & Other Net Current Assets 3.64%
GRAND TOTAL 100.00%

Investment in Top 10 scrips constitutes 43.57% of the portfolio


For SIP Performance please click here

For Scheme Performance please click here


Pursuant to distribution under Income Distribution cum Capital Withdrawal (‘IDCW’) option, NAV of the IDCW option of the scheme(s) would fall to the extent of payout and statutory levy (if applicable). The amounts under IDCW options can be distributed out of investors capital (Equalization Reserve), which is part of sale price that represents realized gains. Past performance may or may not be sustained in future. The above stated distribution rate per unit is net distribution rate after deducting applicable taxes. The above distribution rates are on face value of ₹ 10 per unit.

TER - Regular Plan (%) 2.18%
TER - Direct Plan (%) 1.08%
Portfolio Turnover Ratio 0.73

*The information contained in this report has been obtained from sources considered to be authentic and reliable. This quantitative data does not purport to be an offer for purchase and sale of mutual fund units.
The risk free rate of return considered for calculation of Sharpe ratio is 6.00%, as per 1 day MIBOR rate on the last business day of the month

No of Stocks 49
Portfolio RoE (%) 17.54
EPS Growth (%) 23.20

This product is suitable for investors who are seeking*:

➤ Capital appreciation over long term.
➤ Investment predominantly in a portfolio of equity and equity related securities by following a value investment strategy

*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.

Scheme Riskometer^^
Investors understand that their principal will be at Very High risk


Benchmark (Tier 1) Riskometer^
Benchmark riskometer is at Very High risk


^^Riskometer For Scheme: basis it’s portfolio, ^Riskometer For Benchmark (Nifty 500 TRI): basis it’s constituents; As on April 30, 2025

For complete portfolio, kindly refer the website https://www.barodabnpparibasmf.in/
Mutual Fund investments are subject to market risks, read all scheme related documents carefully.